Philipp Schwabl

List of Publications by Year
in descending order

91 papers	4,599 citations	136940 32 h-index	106340 65 g-index
91 all docs	91 docs citations	91 times ranked	4610 citing authors

#	Article	IF	Citations
1	Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal Hypertension. Clinical Gastroenterology and Hepatology, 2022, 20, e251-e266.	4.4	25
2	Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites. Thrombosis and Haemostasis, 2022, 122, 353-362.	3.4	7
3	Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death. Clinical Gastroenterology and Hepatology, 2022, 20, 1362-1373.e6.	4.4	39
4	Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies. Hepatology, 2022, 75, 610-622.	7.3	18
5	The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices. Digestive and Liver Disease, 2022, 54, 500-508.	0.9	11
6	Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis. Platelets, 2022, 33, 879-886.	2.3	5
7	HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. Journal of Hepatology, 2022, 76, 812-821.	3.7	59
8	Splenectomy ameliorates portal pressure and anemia in animal models of cirrhotic and non-cirrhotic portal hypertension. Advances in Medical Sciences, 2022, 67, 154-162.	2.1	4
9	The â€˜Viennese epidemicâ€™ of acute HCV in the era of directâ€acting antivirals. Journal of Viral Hepatitis, 2022, 29, 385-394.	2.0	10
10	Angiopoietin 2 levels decrease after HCV-cure and reflect the evolution of portal hypertension. Digestive and Liver Disease, 2022, 54, 1222-1229.	0.9	2
11	Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis. Journal of Gastroenterology, 2022, 57, 99-110.	5.1	11
12	Acute hemodynamic response to propranolol predicts bleeding and nonbleeding decompensation in patients with cirrhosis. Hepatology Communications, 2022, 6, 2569-2580.	4.3	6
13	Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease. Liver International, 2022, 42, 2501-2512.	3.9	16
14	Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes. Gut, 2021, 70, 1758-1767.	12.1	51
15	Iron deficiency-induced thrombocytosis increases thrombotic tendency in rats. Haematologica, 2021, 106, 782-794.	3.5	20
16	Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. Hepatology, 2021, 73, 1275-1289.	7.3	45
17	Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. Journal of Hepatology, 2021, 74, 819-828.	3.7	96
18	Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver disease. Digestive and Liver Disease, 2021, 53, 345-352.	0.9	0

#	Article	IF	Citations
19	Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension. Liver International, 2021, 41, 799-809.	3.9	27
20	The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model. Biomedicines, 2021, 9, 60.	3.2	37
21	Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR. Journal of Personalized Medicine, 2021, 11, 281.	2.5	5
22	The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes. Hepatology International, 2021, 15, 1160-1173.	4.2	12
23	Detection of Microplastic in Human Placenta and Meconium in a Clinical Setting. Pharmaceutics, 2021, 13, 921.	4.5	155
24	Nuclear receptors in liver fibrosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166235.	3.8	23
25	Direct patient-physician communication via aÂhepatitisÂC hotline facilitates treatment initiation in patients with poor adherence. Wiener Klinische Wochenschrift, 2021, 133, 452-460.	1.9	7
26	Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease. American Journal of Gastroenterology, 2021, 116, 723-732.	0.4	105
27	Hepatitis C Virus RNA Is Commonly Detectable in Rectal and Nasal Fluids of Patients With High Viremia. Clinical Infectious Diseases, 2020, 71, 1292-1299.	5.8	16
28	Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferonâ€Free Therapy. Hepatology, 2020, 71, 1023-1036.	7.3	112
29	Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease. Liver International, 2020, 40, 194-204.	3.9	45
30	Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension. Liver International, 2020, 40, 393-404.	3.9	20
31	Microplastics in hot water. Nature Food, 2020, 1, 671-672.	14.0	19
32	Thromboelastometry in patients with advanced chronic liver disease stratified by severity of portal hypertension. Hepatology International, 2020, 14, 1083-1092.	4.2	9
33	Assessment of Human Health Risks Posed by Nano-and Microplastics Is Currently Not Feasible. International Journal of Environmental Research and Public Health, 2020, 17, 8832.	2.6	45
34	Comparison of the diagnostic quality of aspiration and core-biopsy needles for transjugular liver biopsy. Digestive and Liver Disease, 2020, 52, 1473-1479.	0.9	6
35	Soluble guanylyl cyclase stimulation and phosphodiesteraseâ€5Âinhibition improve portal hypertension and reduce liver fibrosis in bile ductâ€"ligated rats. United European Gastroenterology Journal, 2020, 8, 1174-1185.	3.8	20
36	Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis. Hepatology International, 2020, 14, 1093-1103.	4.2	12

#	Article	IF	Citations
37	Nonâ€invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease. Liver International, 2020, 40, 1713-1724.	3.9	14
38	Bioimpedance spectroscopy for fluid status assessment in patients with decompensated liver cirrhosis: Implications for peritoneal dialysis. Scientific Reports, 2020, 10, 2869.	3.3	5
39	Novel reliability criteria for controlled attenuation parameter assessments for nonâ€invasive evaluation of hepatic steatosis. United European Gastroenterology Journal, 2020, 8, 321-331.	3.8	30
40	Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy. Journal of Visualized Experiments, 2020, , .	0.3	51
41	Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease. Liver International, 2019, 39, 127-135.	3.9	39
42	Vascular Targets for the Treatment of Portal Hypertension. Seminars in Liver Disease, 2019, 39, 483-501.	3.6	19
43	The impact of hepatic steatosis on portal hypertension. PLoS ONE, 2019, 14, e0224506.	2.5	10
44	Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension. Digestive Diseases and Sciences, 2019, 64, 3642-3651.	2.3	8
45	Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 2164-2172.	2.8	9
46	Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication. AIDS Patient Care and STDs, 2019, 33, 197-206.	2.5	10
47	High efficacy of interferonâ€free therapy for acute hepatitis C in HIVâ€positive patients. United European Gastroenterology Journal, 2019, 7, 507-516.	3.8	22
48	Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information. Digestive and Liver Disease, 2019, 51, 1144-1151.	0.9	23
49	Ascitic fluid polymorphic nuclear cell count impacts on outcome of cirrhotic patients with ascites. United European Gastroenterology Journal, 2019, 7, 651-661.	3.8	7
50	Programmed cell death proteinâ€1 (<scp>PD</scp>â€1)â€targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre realâ€world cohort. Alimentary Pharmacology and Therapeutics, 2019, 49, 1323-1333.	3.7	106
51	Detection of Various Microplastics in Human Stool. Annals of Internal Medicine, 2019, 171, 453-457.	3.9	939
52	ePTFEâ€TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis. Liver International, 2018, 38, 1036-1044.	3.9	28
53	Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease. European Journal of Gastroenterology and Hepatology, 2018, 30, 291-295.	1.6	10
54	Non-invasive liver fibrosis assessment and HCV treatment initiation within aÂsystematic screening program in HIV/HCV coinfected patients. Wiener Klinische Wochenschrift, 2018, 130, 105-114.	1.9	14

#	Article	IF	Citations
55	Point Shear Wave Elastography for Non-invasive Assessment of Liver Fibrosis in Patients with Viral Hepatitis. Ultrasound in Medicine and Biology, 2018, 44, 2578-2586.	1.5	11
56	Comparison of three cut-offs to diagnose clinically significant portal hypertension by liver stiffness in chronic viral liver diseases: a meta-analysis. European Radiology, 2018, 28, 5221-5230.	4.5	20
57	The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats. Scientific Reports, 2018, 8, 9372.	3.3	39
58	Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats. Journal of Visualized Experiments, 2018, , .	0.3	5
59	Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding â€“ A two decades experience. PLoS ONE, 2018, 13, e0189414.	2.5	20
60	Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function. Wiener Klinische Wochenschrift, 2018, 130, 446-455.	1.9	41
61	Plasma renin concentration represents an independent risk factor for mortality and is associated with liver dysfunction in patients with cirrhosis. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 184-190.	2.8	17
62	Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices. Scandinavian Journal of Gastroenterology, 2017, 52, 1-8.	1.5	13
63	Metabolic preconditioning protects BSEP/ABCB11âˆ’/âˆ’ mice against cholestatic liver injury. Journal of Hepatology, 2017, 66, 95-101.	3.7	51
64	The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. Journal of Hepatology, 2017, 66, 724-733.	3.7	130
65	Austrian consensus guidelines on the management and treatment of portal hypertension (BillrothÂIII). Wiener Klinische Wochenschrift, 2017, 129, 135-158.	1.9	111
66	Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice. Digestive and Liver Disease, 2017, 49, 1360-1367.	0.9	28
67	Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna. Wiener Klinische Wochenschrift, 2017, 129, 517-526.	1.9	9
68	Novel treatment options for portal hypertension. Gastroenterology Report, 2017, 5, 90-103.	1.3	25
69	Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease. Aids, 2016, 30, 1039-1047.	2.2	42
70	The trigger matters â€“ outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites. Liver International, 2016, 36, 1649-1656.	3.9	10
71	Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease. Medicine (United States), 2016, 95, e4061.	1.0	18
72	Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. Journal of Hepatology, 2016, 65, 692-699.	3.7	245

#	Article	IF	Citations
73	Liver Capsule: FXR agonists against liver disease. Hepatology, 2016, 64, 1773-1773.	7.3	15
74	Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure. Wiener Klinische Wochenschrift, 2016, 128, 414-420.	1.9	1
75	Advances in the management of HIV/HCV coinfection. Hepatology International, 2016, 10, 424-435.	4.2	47
76	Prognosis of cirrhotic patients with fungiascites and spontaneous fungal peritonitis (SFP). Journal of Hepatology, 2016, 64, 1452-1454.	3.7	13
77	Impact of acute kidney injury on prognosis of patients with liver cirrhosis and ascites: A retrospective cohort study. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1657-1665.	2.8	37
78	Response-Guided Boceprevir-based Triple Therapy in HIV/HCV-coinfected Patients: The HIVCOBOC-RGT Study. Journal of Infectious Diseases, 2015, 211, 729-735.	4.0	10
79	Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites. Liver International, 2015, 35, 2121-2128.	3.9	72
80	New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension. Liver International, 2015, 35, 381-390.	3.9	111
81	Revisiting liver disease progression in HIV/HCVâ€coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3. Liver International, 2015, 35, 876-885.	3.9	32
82	Circulating MiRNA-122 Levels Are Associated with Hepatic Necroinflammation and Portal Hypertension in HIV/HCV Coinfection. PLoS ONE, 2015, 10, e0116768.	2.5	21
83	The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection. PLoS ONE, 2015, 10, e0143429.	2.5	23
84	PRO-C3-Levels in Patients with HIV/HCV-Co-Infection Reflect Fibrosis Stage and Degree of Portal Hypertension. PLoS ONE, 2014, 9, e108544.	2.5	29
85	Nonselective Î² Blockers Increase Risk for Hepatorenal Syndrome and Death in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis. Gastroenterology, 2014, 146, 1680-1690.e1.	1.3	336
86	Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. Journal of Hepatology, 2014, 60, 1135-1142.	3.7	39
87	Proton Pump Inhibitor Intake neither Predisposes to Spontaneous Bacterial Peritonitis or Other Infections nor Increases Mortality in Patients with Cirrhosis and Ascites. PLoS ONE, 2014, 9, e110503.	2.5	55
88	Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling. Liver International, 2013, 33, 561-568.	3.9	16
89	Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut, 2013, 62, 1634-1641.	12.1	275
90	Noninvasive screening for liver fibrosis and portal hypertension by transient elastographyâ€"a large single center experience. Wiener Klinische Wochenschrift, 2012, 124, 395-402.	1.9	93

#	Article	IF	Citations
91	Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. Journal of Hepatology, 2009, 51, 865-873.	3.7	95